Dr. Robert Orlowski, head of the myeloma section at MD Anderson Cancer Center, details a number of updates from the 2011 American Society of Hematology meeting. He explains data presented regarding newer drugs carfilzomib and bortezomib and a range of studies looking at consolidation and maintenance therapy following a stem cell transplant. He also talks about the expansion of newer tests to detect Minimal Residual Disease or MRD.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…